Medera Inc., a clinical-stage biopharmaceutical company, announced positive results from the Phase 1b portion of its MUSIC-HFrEF trial, evaluating the gene therapy SRD-001 for heart failure with reduced ejection fraction (HFrEF). An independent Data and Safety Monitoring Board (DSMB) recommended proceeding to Phase 2 based on data from nine patients across two dose cohorts. The Phase 2 trial will be a placebo-controlled study with a larger patient population, commencing enrollment in Q2 2025.
This advancement is particularly important given the significant unmet need in HFrEF treatment. HFrEF affects millions globally and is often a progressive, irreversible condition with limited effective therapies. Positive clinical data for a novel gene therapy like SRD-001 offers a potential breakthrough for patients facing debilitating symptoms and high mortality rates. This progress also validates Medera’s approach of leveraging its “mini-Heart” technology platform for human-specific disease modeling and drug discovery.
The DSMB’s recommendation is based on data from all participants in the Phase 1b portion, which included both low-dose (3×10^13 vg) and high-dose (4.5×10^13 vg) cohorts. While topline data with 12-month follow-up will be released later, the DSMB’s clearance to proceed suggests a positive safety and efficacy profile for the high dose, which will be used in the Phase 2 trial. The Phase 2 portion is designed as a placebo-controlled study with a 1:1 randomization, allowing for a more robust assessment of SRD-001’s therapeutic potential.
The positive DSMB recommendation and subsequent move to a larger, placebo-controlled Phase 2 trial marks a crucial step in SRD-001’s development. Success in Phase 2 could significantly accelerate the path towards regulatory approval and potentially offer a much-needed new treatment option for HFrEF patients. This also strengthens Medera’s position in the cardiovascular disease space, particularly given their broader pipeline of gene therapies targeting other cardiac conditions. The upcoming release of Phase 1b topline data and commencement of Phase 2 enrollment will be key inflection points to watch closely.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
